Amicus Therapeutics (FOLD) News Today $9.13 -0.36 (-3.79%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$9.26 +0.13 (+1.37%) As of 03/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency ActMarch 3 at 2:04 PM | globenewswire.comAmicus Therapeutics to Present at Upcoming Investor Conferences in March 2025February 27, 2025 | globenewswire.comY Intercept Hong Kong Ltd Has $1.14 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Y Intercept Hong Kong Ltd increased its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 245.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 120,958 shares of the biopharmaceutical coFebruary 27, 2025 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by HealthInvest Partners ABHealthInvest Partners AB lifted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 326,840 shares of the biopharmaceutical companyFebruary 24, 2025 | marketbeat.comAmicus Therapeutics: Strategic Market Expansion and Robust Sales Drive Buy RatingFebruary 23, 2025 | tipranks.comState of New Jersey Common Pension Fund D Buys 50,236 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)State of New Jersey Common Pension Fund D increased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 29.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 220,500 shares of the biopharmaceuFebruary 23, 2025 | marketbeat.comTranscend Capital Advisors LLC Acquires 37,059 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Transcend Capital Advisors LLC boosted its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 11.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 363,913 shares of the biopharmaceutical comFebruary 22, 2025 | marketbeat.comWells Fargo & Company Issues Pessimistic Forecast for Amicus Therapeutics (NASDAQ:FOLD) Stock PriceFebruary 22, 2025 | americanbankingnews.comAmicus Therapeutics CEO Campbell Bradley sells $4,000 in stockFebruary 21, 2025 | investing.comWells Fargo & Company Cuts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $17.00Wells Fargo & Company reduced their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday.February 21, 2025 | marketbeat.comNeedham & Company LLC Reaffirms Hold Rating for Amicus Therapeutics (NASDAQ:FOLD)Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday.February 21, 2025 | marketbeat.comAmicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy ChangesFebruary 21, 2025 | tipranks.comAmicus price target lowered to $17 from $18 at Wells FargoFebruary 20, 2025 | markets.businessinsider.comAmicus Therapeutics CEO says biotech firm is on path to $1B in revenueFebruary 20, 2025 | bizjournals.comAmicus Therapeutics CEO says biotech firm is on path to $1B in revenueFebruary 20, 2025 | bizjournals.comAmicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 20, 2025 | finance.yahoo.comAmicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...February 20, 2025 | finance.yahoo.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call TranscriptFebruary 20, 2025 | msn.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2024 Earnings Call TranscriptFebruary 20, 2025 | msn.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing EarningsAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down on Disappointing EarningsFebruary 20, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Posts Earnings Results, Misses Estimates By $0.07 EPSAmicus Therapeutics (NASDAQ:FOLD - Get Free Report) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Amicus Therapeutics had a negative return on equity of 15.97% and a negative net margin of 21.21%.February 20, 2025 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Lowered to "Hold" Rating by StockNews.comStockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday.February 20, 2025 | marketbeat.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the FirmFebruary 19, 2025 | businesswire.comAmicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call TranscriptFebruary 19, 2025 | seekingalpha.comAmicus Therapeutics, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 19, 2025 | seekingalpha.comAmicus expects to surpass $1B in total sales in 2028February 19, 2025 | markets.businessinsider.comAmicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate UpdatesFebruary 19, 2025 | markets.businessinsider.comAmicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate UpdatesFebruary 19, 2025 | globenewswire.comPeregrine Capital Management LLC Buys 135,716 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Peregrine Capital Management LLC lifted its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 18.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 880,517 shares of the biopharmaceutical company's stock afterFebruary 19, 2025 | marketbeat.comAmicus Therapeutics (FOLD) to Release Quarterly Earnings on WednesdayAmicus Therapeutics (NASDAQ:FOLD) will be releasing earnings before the market opens on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=664474)February 19, 2025 | marketbeat.com3 Emerging Biotech Firms Pioneering Next-Gen TherapiesFebruary 18, 2025 | stocknews.comRice Hall James & Associates LLC Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Rice Hall James & Associates LLC raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 41.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,371,080 shares of the biopharmaceuticaFebruary 18, 2025 | marketbeat.comKuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law FirmFebruary 17, 2025 | gurufocus.comKuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law FirmFebruary 17, 2025 | globenewswire.comRedmile Group, LLC's Strategic Acquisition in Amicus Therapeutics IncFebruary 15, 2025 | gurufocus.comFiera Capital Corp Reduces Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Fiera Capital Corp lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 5.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,037,248 shares of the biopharmaceutical company's stock after sellingFebruary 14, 2025 | marketbeat.comStockNews.com Upgrades Amicus Therapeutics (NASDAQ:FOLD) to BuyStockNews.com raised shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Wednesday.February 12, 2025 | marketbeat.comTD Cowen Reaffirms Their Buy Rating on Amicus (FOLD)February 10, 2025 | markets.businessinsider.comAmicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025February 10, 2025 | globenewswire.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and sevenFebruary 9, 2025 | marketbeat.comabrdn plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)abrdn plc lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 23.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,380,775 shares of the biopharmaceutical company's stock afFebruary 8, 2025 | marketbeat.comMorgan Stanley Reaffirms Their Hold Rating on Amicus (FOLD)February 7, 2025 | markets.businessinsider.comTempus Wealth Planning LLC Buys Shares of 27,523 Amicus Therapeutics, Inc. (NASDAQ:FOLD)Tempus Wealth Planning LLC bought a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 27,523 shares of the biopharmaceutical company's stock, valued at approximately $259,000. A nFebruary 5, 2025 | marketbeat.comAmicus Therapeutics Inc (FOLD) Showcases Extensive Research at WORLDSymposium 2025February 3, 2025 | gurufocus.comAmicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025February 3, 2025 | globenewswire.comZacks Research Has Negative Outlook of FOLD FY2025 EarningsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Stock analysts at Zacks Research decreased their FY2025 earnings per share estimates for shares of Amicus Therapeutics in a note issued to investors on Thursday, January 30th. Zacks Research analyst R. Department now expects that the biopharFebruary 3, 2025 | marketbeat.comKuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law FirmJanuary 30, 2025 | investing.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Position Decreased by Inspire Investing LLCInspire Investing LLC lowered its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 38.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 43,151 shares of the biopharmaceutical company's stock afterJanuary 26, 2025 | marketbeat.comNCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement CasesJanuary 23, 2025 | globenewswire.comLeerink Partnrs Issues Optimistic Outlook for FOLD EarningsAmicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) - Analysts at Leerink Partnrs boosted their Q4 2024 earnings per share estimates for Amicus Therapeutics in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceuticJanuary 22, 2025 | marketbeat.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼1.240.70▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼55▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EXEL News EXAS News RGEN News HALO News MDGL News ALKS News IONS News LGND News BCRX News DVAX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
